Literature DB >> 12419038

Fertilization, embryonic development and pregnancy losses with intracytoplasmic sperm injection for surgically-retrieved spermatozoa.

Anthony R Anderson1, Klaus E Wiemer, Margaret L Weikert, Melissa L Kyslinger.   

Abstract

Prior to the development of intracytoplasmic sperm injection (ICSI), azoospermic and severely oligozoospermic men had little to no chance of having a biological child. In this study, ICSI outcome in 454 transfers with ejaculated spermatozoa and 59 transfers with surgically retrieved spermatozoa were evaluated. Normal fertilization rate using ejaculated spermatozoa was 75% of 5995 oocytes, and 73% of 751 oocytes for surgically retrieved spermatozoa; with ongoing pregnancy rates of 53% (242/454) and 61% (36/59) respectively. Surgically retrieved spermatozoa significantly (P < 0.05) impacted 1PN oocytes (6.1%, 46/751), severely fragmented embryos (8.8%, 46/550) and incidence of pregnancy loss (11%, 4/36). When using ejaculated spermatozoa, incidence of 1PN oocytes, severely fragmented embryos and pregnancy loss was 2.9% (177/5995), 4.5% (200/4365), 2.4% (6/242) respectively.

Entities:  

Mesh:

Year:  2002        PMID: 12419038     DOI: 10.1016/s1472-6483(10)61616-1

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  3 in total

Review 1.  The use of in vitro fertilization in the management of male infertility: what the urologist needs to know.

Authors:  Sahar M Stephens; Daniel M Arnett; Randall B Meacham
Journal:  Rev Urol       Date:  2013

2.  Optimal use of fresh and frozen-thawed testicular sperm for intracytoplasmic sperm injection in azoospermic patients.

Authors:  Bin Wu; Diana Wong; Suzhen Lu; Stephen Dickstein; Marta Silva; Timothy J Gelety
Journal:  J Assist Reprod Genet       Date:  2005-12       Impact factor: 3.412

3.  Cryopreservation of testicular and epididymal sperm: techniques and clinical outcomes of assisted conception.

Authors:  Bhushan K Gangrade
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.